Search Medical Condition
Please enter condition
Please choose location from dropdown

Tyne and Wear, United Kingdom Clinical Trials

A listing of Tyne and Wear, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (272) clinical trials

Validation of the Spasticity Related Quality of Life Questionnaire

The study qualifies as interventional not because of the use of an investigational product, but because the imposed specific data collection procedures include multiple questionnaire assessments and one on-site visit not necessarily part of routine clinical practice.

Phase N/A

0.62 miles

Learn More »

HuMax-AXL-ADC Safety Study in Patients With Solid Tumors

The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and an expansion part (phase IIa). The dose escalation part has two dose escalation arms: the first arm investigates a once every 3 weeks (1Q3W) dosing schedule and the second arm investigates a three ...

Phase

1.18 miles

Learn More »

Phase 2b Study in NASH to Assess IVA337

Randomized (stratified on diabetes), placebo-controlled, double-blind, parallel-assignment, dose-range multicenter study There are 3 parallel treatment groups: placebo, IVA337 800mg once a day (Quaque Die, QD) and IVA337 1200mg QD (identical tablets of 400mg IVA337 or placebo). Both, patient and investigator are blinded. For each patient, the study duration will be ...

Phase

1.18 miles

Learn More »

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody ...

Phase

1.18 miles

Learn More »

An Open-Label Multi-Centre Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

This is an open-label, multi-center, study to determine the short and long term safety of fixed doses of durvalumab 1500 mg + tremelimumab 75 mg combination therapy or durvalumab 1500 mg monotherapy in patients with advanced solid malignancies. This study is modular in design, one or more of the modules ...

Phase

1.18 miles

Learn More »

Effect of Mepolizumab in Severe Bilateral Nasal Polyps

Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex. The presence of polyps can cause long-term symptoms such as prominent nasal obstruction, post-nasal drip, ...

Phase

1.18 miles

Learn More »

Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

The primary objective is to evaluate the benefit of the SmartDelay algorithm in patients with a prolonged RV-LV interval.

Phase N/A

1.18 miles

Learn More »

An Investigational Immuno-therapy Study for Safety and Efficacy of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

A study to evaluate the safety and efficacy of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

Phase

1.18 miles

Learn More »

A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Parts A and B will consist of 3 periods: Screening, Treatment and Follow-up. Screening Period The Screening Period starts 28 days ( 3 days) prior to first dose of CC-90011. The informed consent document (ICD) must be signed and dated by the subject and the administering staff prior to the ...

Phase

1.18 miles

Learn More »

Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery

The EMINENT study is a prospective, multi-center study confirming the superior effectiveness of the ELUVIA stent versus Self-Expanding Bare Nitinol Stents in the treatment of lesions 30-140 mm long located in the femoropopliteal arteries in subjects with symptoms classified as Rutherford categories 2-4. The study is a 2:1 randomized (ELUVIA ...

Phase N/A

1.18 miles

Learn More »